Persistence and adherence with dementia pharmacotherapy: Relevance of patient, provider, and system factors

Canadian Journal of Psychiatry

Volumn 59, Issue 12, 2014, Pages 624-631

  Maxwell, Colleen J ^a   Stock, Kathryn ^a   Seitz, Dallas ^b   Herrmann, Nathan ^c  

^a UNIVERSITY OF WATERLOO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Adherence; Alzheimer disease; Cholinesterase; Inhibitors; Memantine; Persistence

Indexed keywords

DONEPEZIL; GALANTAMINE; NOOTROPIC AGENT; RIVASTIGMINE;

CLINICAL TRIAL (TOPIC); DEMENTIA; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; REIMBURSEMENT; REVIEW; SOCIAL STATUS; UNSPECIFIED SIDE EFFECT;

DEMENTIA; HUMANS; MEDICATION ADHERENCE;

EID: 84919421426     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371405901203     Document Type: Review

References (103)

1. World Health Organization (WHO) and Alzheimer's Disease International. Dementia: a public health priority. Geneva (CH): WHO; 2012.
2. Alzheimer Society of Canada. Rising tide: the impact of dementia on Canadian Society. Toronto (ON): Alzheimer Society of Canada; 2010.
3. Hogan DB, Bailey P, Black S, et al. Diagnosis and treatment of dementia Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ. 2008;179:1019-1026.
4. Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ. 2008;179:1279-1287.
5. Herrmann N, Lanctô t KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer Res Ther. 2013;5(Suppl 1):S5.
6. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22:806-812.
7. Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006;21:353-363.
8. Doody RS, Geldmacher DS, Gordon B, et al, for the Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol. 2001;58: 427-433.
9. Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000;10:195-203.
10. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366:893-903.
11. Scarpini E, Bruno G, Zappalà G, et al. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis. 2011;26:211-220.
12. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J Int Med Res. 2006;34:339-347.
13. Daiello LA, Ott BR, Lapane KL, et al. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacothe r. 2009;7:74-83.
14. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD005593.
15. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;2:CD003154.
16. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia a nd cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;3:CD006504.
17. Kaduszkiewicz H, Zimmerman T, Beck-Bornholdt H-P, et al. Cholinesterase inhibitors for patients with Alzhei mer's disease: systematic review of randomised clinical trials. Br Med J. 2005;331:321-327.
18. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine f or treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-397.
19. Knapp M, Iemmi V, Romeo R. Dementia care costs and outcomes: a systematic review. Int J Geriatr Psychiatry. 2013;28:551-561.
20. Bond M,Rogers G,Peters J,et al., The effectiveness and costeffectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No 111 a systematic review and economic model, Health Technol Assess. 2012;16, 1-470.
21. Cappell J, Herrmann N, Cornish S, et al. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. CNS Drugs. 2010;24:909-927.
22. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet. 2004;363:2105-2115.
23. Rosenblatt A, Samus QM, Onyike CU, et al. Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. Int J Geriatr Psychiatry. 2008;23:178-184.
24. Lo pez OL, Becker JT, Saxton J, et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibitors. J Am Geriatr Soc. 2005;53:83-87.
25. Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-944.
26. Acri T, G ross R. Studies of medication adherence. In: Strom BL, Kimmel SE, Hennessy S, editors. Textbook of pharmacoepidemiology. 2nd ed. Hoboken (NJ): John Wiley & Sons, Ltd; 2013.
27. Campbell NL, Boustani MA, Skopelja EN, et al. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother. 2012;10:165-177.
28. Arlt S, Lindner R, Rö sler A, et al. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25:1033-1047.
29. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23:2705-2713.
30. Brady R, Weinman J. Adherence to cholinesterase inhibitors in Alzheimer's disease: a review. Dement Geriatr Cogn Disord. 2013;35:351-363.
31. Thiruchselvam T, Naglie G, Moineddin R, et al. Risk factors for medication nonadherence in older adults with cognitive impairment who live alone. In t J Geriatr Psychiatry. 2012;27:1275-1282.
32. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. A m J Geriatr Pharmacother. 2011;9:11-23.
33. Vik SA, Hogan DB, Patten SB, et al. Medication nonadherence and subsequent risk of hospitalization and mortality in older adults. Drugs Aging. 2006;23:345-356.
34. Taipale H, Tanskanen A, Koponen M, et al. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol. 2014;29:216-223.
35. Haider B, Schmidt R, Schweiger C, et al. Medication adherence in patients with dementia: an Austrian cohort study. Alzheimer Dis Assoc Disord. 2014;28:128-133.
36. Gardette V, Lapeyre-Mestre M, Piau A, et al. A 2-year prospective cohort study of antidementia drug non-persistency in mildto-moderate Alzheimer's disease in Europe: predictors of discontinuation and switch in the ICTUS study. CNS Drugs. 2014; 28:157-170.
37. Saleh S, Kirk A, Morgan DG, et al. Less education predicts anticholinesterase discontinuation in dementia patients. Can J Neurol Sci. 2013;40:684-690.
38. Brewer L, Bennett K, McGreevy C, et al. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol. 2013;69:1467-1475.
39. Olazaran J, Navarro E, Rojo JM. Persistence of cholinesterase inhibitor treatment in dementia: insights from a naturalistic study. Dement Geriatr Cogn Dis Extra. 2013;3:48-59.
40. Le Couteur DG, Robinson M, Leverton A, et al. Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease. Australas J Ageing. 2012;31:164-169.
41. van den Bu ssche H, Kaduszkiewicz H, Koller D, et al. Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up. Int Clin Psychopharmacol. 2011;26:225-231.
42. Mansour D,Wong R,Kuskowski M,et al., Discontinuation of acetylcholinesterase inhibitor treatment in the nursing home, Am J Geriatr Pharmacother, 2011, 9: 345-350.
43. Krö ger E, van Marum R, Souverein P, et al. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study. Drugs Aging. 2010;27:663-675.
44. Amuah JE, Hogan DB, Eliasziw M, et al. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19:670-679.
45. Pariente A, Pinet M, Moride Y, et al. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf. 2010;19:680-686.
46. Gadzhanova S, Roughead L, Mackson J. Anticholinesterase duration in the Australian veteran population. Aust N Z J Psychiatry. 2010;44:469-474.
47. Gardette V, Andrieu S, Lapeyre-Mestre M, et al. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, c ohort study. CNS Drugs. 2010;24:431-442.
48. Herrmann N, Binder C, Dalziel W, et al. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health databa se study. Drugs Aging. 2009;26:403-407.
49. Umegaki H, Itoh A, Suzuki Y, et al. Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. Int Psychogeriatr. 2008;20:800-806.
50. Massoud F, Dorais M, Charbonneau C, et al. Drug utilization review of cholinesterase inhibitors in Quebec. Can J Neurol Sci. 2008;35:508-509.
51. Abughosh SM, Kogut SJ. Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Prefer Adherence. 2008;2:79-85.
52. Mucha L, Shaohung S, Cuffel B, et al. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm. 2008;14:451-461.
53. Sun Y, Lai M-S, Lu C-J, et al. How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study. Eur J Neurol. 2008;15:278-283.
54. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc. 2007;55:1517-1523.
55. Suh D-C, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging. 2005;22:695-707.
56. Mauskopf JA, Par amore C, Lee WC, et al. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm. 2005;11:231-239.
57. Singh G, Thomas SK, Arco na SK, et al. Treatment persistency with rivastigmine and donepezil in a large state Medicaid program. J Am Geriatr Soc. 2005;53:1269-1270.
58. Dybicz SB, Keohane DJ, Erwin WG, et al. Pa tterns of cholinesterase inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother. 2006;4:154-160.
59. Kogut SJ, El-Maouche D, Abughosh SM. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy. 2005;25:1729-1735.
60. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord. 2002;16:49-51.
61. Blais L, Kettani FZ, Perreault S, et al. Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. J Am Geriatr Soc. 2009;57(2):366-368.
62. Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin. 2010;26:1957 -1965.
63. Poon I,Lal LS,Ford ME,et al., Racial/ethnic disparities in medication use am ong veterans with hypertension and dementia: a national cohort study, Ann Pharmacother., 2009, 43, 185-193.
64. Tian H, Abouzaid S, Chen W, et al. Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study. Alzheimer Dis Assoc Disord. 2013;27:182-186.
65. Lopez-Pousa S, Arranz FJ. Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice. Patient Prefer Adherence. 2013;7:47-54.
66. Schwalbe O, Scheerans C, Freiberg I, et al. Compliance assessment of ambulat ory Alzheimer patients to aid therapeutic decisions by healthcare professionals. BMC Health Serv Res. 2010;10:232.
67. Zhu CW, Livote EE, Kahle-Wrobleski K, et al. Longitudinal medication usage in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2010;24:354-359.
68. Schneider LS, Insel PS, Weiner MW, for the Alzheimer's Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011;68:58-66.
69. Maxwell CJ, Vu M, Hogan DB, et al. Patterns of dementia pharmacotherapy in a population-based cohort of home care clients. Drugs Aging. 2013;30:569-585.
70. Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11:e274-e285.
71. Belle SH, Zhang S, Czaja SJ, et al. Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results fro m the Resources for Enhancing Alzheimer's Caregiver Health (REACH) project. Am J Geriatr Psychiatry. 2004;12:250-257.
72. Seitz DP, Gruneir A, Conn DK, et al. Cholinesterase inhibitor use in US nursing homes: results from the National Nursing Home Survey. J Am Geriatr Soc. 2009;57:2269-2274.
73. Haywood WM, Mukaetova-Ladinska EB. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease. Am J Geriatr Pharmacother. 2006;4:273-286.
74. Hö er A, Gothe H, Khan ZM, et al. Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. J Hum Hypertens. 2007;21:744-746.
75. Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14:795-803.
76. Hernandez S, McClendon MJ, Zhou X-H, et al. Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables. J Alzheimers Dis. 2010;19:665-672.
77. Gilligan AM, Malone DC, Warholak TL, et al. Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations. Am J Geriatr Pharmacother. 2012;10:303- 312.
78. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
79. Goldman PD, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-69.
80. Piette JD, Heisler M, Wagner TH. Medicat ion characteristics beyond cost alone influence decisions to underuse pharmacotherapy in response to financial pressures. J Clin Epidemiol. 2006;59:739-746.
81. Pariente A, Fourrier-Ré glat A, Ducruet T, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172:648-653.
82. Hernandez RK, Farwell W, Cantor MD, et al. Cholinestera se inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. J Am Geriatr Soc. 2009;57:1997-2003.
83. Gill SS, Anderson GM, Fischer HD, e t al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors. A population-based cohort study. Arch Intern Med. 2009;169:867-873.
84. Carnahan RM,Lund BC,Perry PJ et al., The concurrent use of anticholinergics and cholinesterase inhibitors, rare event or common practice? J Am Geriatr Soc., 2004, 52, 2082-2087.
85. Boada M, Arranz FJ. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord. 2013;35:23-33.
86. W inblad B, Cummings J, Andreasen N, et al. A six-month doubleblind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456-467.
87. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007;2 2:485-491.
88. Hogan DB, Goldlist B, Naglie G, et al. Comparison studies of cholinesterase inhibitors for Alzheimer's disease. Lancet Neurol. 2004;3:622-626.
89. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician followup and provider continuity are associated with long term medication adherence. A study of the dynamics of statin use. Arch Intern Med. 2007;167:847-852.
90. Dhalla IA, Anderson GM, Mamdani MM, et al. Inappropriate prescribing before and after nursing home admission. J Am Geriatr Soc. 2002;50:995-1000.
91. Wata nabe N, Yamamura K, Suzuki Y, et al. Pharmacist-based donepezil outpatient consultation service to improve medication persistence. Patient Prefer Adherence. 2012;6:605-611.
92. Barro-Belaygues N , van Kan GA, Rolland Y, et al. Patterns of dementia treatment use in assisted living facilities: a cross-sectional study of 1975 demented residents. J Am Med Dir Assoc. 2011;12:648-654.
93. Cherubini A, Ruggiero C, Dell'Aquila G, et al. Underrecognition and undertreatment of dementia in Italian nursing homes. J Am Med Dir Assoc. 2012;13:759.e7-e13. doi: 10.1016/j.jamda.2012.05.015. Epub 2012 Jun 23.
94. Hogan DB. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer's disease. Can J Psychiatry. 2014;59(12):618-623.
95. Ritchie CW, Zhinchin G. Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease. Int Psychogeriatr. 2013;25:511-515.
96. Massoud F. Persistence with cholinesterase inhibitor treatment in Alzheimer disease. Can J Neurol Sci. 2013;40:623-624.
97. Parsons C, Hughes CM, Passmore AP, et al. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010;27:435-449.
98. Park-Wyllie LY, Mamdani MM, Li P, et al. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med. 2009;6:e1000157.
99. Gray HL, Jimenez DE, Cucciare MA, et al. Ethnic differences in beliefs regarding Alzheimer disease among dementia family caregivers. Am J Geriatr Psychiatry. 2009;17:925-933.
100. Roberts JS, Connell CM, Cisewski D, et el. Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:19-26.
101. Jacklin KM, Walker JD, Shawande M. The emergence of dementia as a health concern among First Nations populations in Alberta, Canada. Can J Public Health. 2013;104:e39-e44.
102. Finkelstein SA, Forbes DA, Richmond CAM. Formal dementia care among First Nations in Southwestern Ontario. Can J Aging. 2012;31:257-270.
103. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489-495.